Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07224438

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location status: Recruiting

Location contact

Study Coordinator

CONTACT

[email protected]

617-643-2308

About this study

Assignment: All study subjects will undergo the same interventions.

Delivery of Interventions:

  • The subject will undergo a review of their medical history, physical exam, and screening laboratories.
  • A pelvic ultrasound will be performed to assess baseline follicular size.
  • A pump will be placed to administer pulsatile SC kisspeptin for two weeks.
  • During the course of kisspeptin administration, subjects will
  • Undergo q10 min blood sampling (approximately 4 sessions, 2 hours each)
  • Undergo pelvic ultrasounds (approximately 4 sessions)
  • Optional q10 min sampling up to 10 hours may take place before and after the course of kisspeptin

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female
  • Ages 18-45 years
  • Acquired HH (hypothalamic amenorrhea, aka functional hypogonadotropic hypogonadism)
  • Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg)
  • Hemoglobin no less than 0.5 g/dL below the lower limit of the reference range for normal women
  • Negative serum hCG pregnancy test
  • No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis OR willing to complete an appropriate washout for that particular medication and its method of administration
  • If applicable, willing to use birth control methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug

Exclusion criteria

  • Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
  • Excessive alcohol consumption (>10 drinks/week)
  • Active use of illicit drugs
  • Pregnant
  • Trying to become pregnant during protocol participation
  • Breast feeding
  • History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding

Treatment and study plan

Kisspeptin 112-121

Drug

SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)

Other names: Metastin 45-54

Primary outcomes

  1. Change of luteinizing hormone (LH) pulse amplitude

    Time frame: 2 weeks

    Difference in LH amplitude on the first day of kisspeptin administration vs the last day of kisspeptin administration

Other outcomes

  1. The proportion of participants that achieve development of a mature follicle or show evidence of ovulation

    Time frame: 2 weeks

    Mature follicle achievement is defined as evidence of a follicle with maximum diameter ≥18 mm. Evidence of ovulation is defined as detection of a corpus luteum on ultrasound in combination with elevated progesterone level.

Study contacts

Contact information is provided by the study sponsor or research team.

Study Coordinator

CONTACT

[email protected]

617-643-2308

Sponsors and collaborators

Lead sponsor

Stephanie B. Seminara, MD

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Nov 4, 2025
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.